Synapsoft logo
AI Insights from Disclosures
Searching...
OLIPASS CORPORATION 244460
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
OLIPASS CORPORATION's name, OliPass, is a compound word combining 'Oligonucleotide' and 'Pass', referring to the company's proprietary RNA therapeutics platform technology for creating oligonucleotides with excellent cell permeability. The company's platform technology has a mechanism (Exon Skipping) in which OPNA (OliPass Peptide Nucleic Acid), chemically modified by the company to have excellent cell permeability and high nucleic acid affinity, binds to pre-mRNA, the genetic material inside cells, thereby suppressing the generation of normal mRNA (the genetic material that binds to ribosomes to synthesize proteins).
Representative Director Kim Taehyeon
Founded November 16, 2006
Corporation Type KOSDAQ
Industry Classification Manufacture of medicinal chemicals
Corporate number 11011-3562570
Business number 113-86-09261
Phone Number 02-6488-2200
Fax Number 031-8060-8110
Website www.olipass.com
Company Address 16-4 Dongbaekjungang-ro 16beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant